You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Guidelines & Advice
About Guidelines Email Guidelines Team

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

ID: MOAC 1 Nov 2013
Type of Content: Guidelines & Advice, Clinical
Document Status: Archived
Authors:
B. Leber, N. Ismaila, S. Kamel-Reid, M. Rutherford, Molecular Oncology Advisory Committee

Guideline Objective

To determine if testing for DNMT3A mutation in this patient population determines prognosis with standard indication and consolidation therapy, as a guide to choosing alternative treatment if appropriate.

Patient Population

AML patients with a normal cytogenetic profile.

Intended Guideline Users

Clinicians, patients and funding bodies.

Research Question(s)

What is the prognostic value of DNMT3A mutation screening in cytogenetically normal patients with acute myeloid leukemia (AML)?

pdf download Full Report (PDF) (673.38 KB)